Cinacalcet tablets recalled for manufacturing impurity exceeding FDA limits
Dr. Reddy's Laboratories recalls Cinacalcet 30 mg tablets nationwide due to manufacturing defects that produced N-nitroso impurity above FDA recommended limits. Patients should contact their healthcare provider if they are taking an affected lot.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with a theoretical hazard (manufacturing defect producing impurity above safety limits) and no reported adverse events justifies High severity per the rubric's criterion for 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Cinacalcet 30 mg tablets distributed nationwide. The recall involves 285,126 bottles across multiple lot numbers with expiration dates ranging from November 2024 through August 2026.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations that resulted in N-nitroso Cinacalcet impurity above the FDA's recommended interim limit.
Patients taking Cinacalcet from affected lots should contact their healthcare provider to determine if they have been impacted and to discuss next steps. Patients should not discontinue their medication without consulting their healthcare provider, as abrupt discontinuation could affect their medical condition.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Hazard
- nitrosamine
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot# T2200120
- T2200121
- T2200119
- T2200116
- T2200118
- T2200117
- Exp 11/2024
- T2200695
- T2200694
- T2200696
- T2200697
- Exp 01/2025
- T2201426
- T2201428
- T2201432
- T2201427
- T2201430
- T2201429
- T2201431
- Exp 03/2025
UPCs (1)
- 0343598369303
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CINACALCET
- HighCinacalcet prescription drug recalled for nitrosamine impurity and manufacturing deviations
FDA (Drugs) · 2026-04-22
- HighFDA Recalls Cinacalcet Tablets for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-04-22
- HighCinacalcet tablets recalled due to N-nitroso impurity above acceptable limits
FDA (Drugs) · 2026-04-22
- HighDrug Recall: Cinacalcet tablets contain excess nitrosamine impurity
FDA (Drugs) · 2025-12-17
- HighCinacalcet tablets recalled for nitrosamine impurity above acceptable limits
FDA (Drugs) · 2025-12-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27